title: Alterations of BAT-26 identify a subset of gastric cancer with distinct clinicopathologic features and better postoperative prognosis.
abstract: OBJECTIVE
  Gastrointestinal tumors with microsatellite instability represent a replication error-positive phenotype. BAT-26, a repeat of 26 deoxyadenosine localized in intron 5 of hMSH2 gene, has been reported as a reliable indicator of replication error phenotype in colorectal cancers. This study investigated whether BAT-26 is a useful marker for a mutator phenotype with distinct clinicopathologic features in gastric cancer.
  
  
  METHODS
  One hundred and nineteen gastric cancer tissues and matched non-tumor tissue were examined by polymerase chain reactions with electrophoresis for 9 dinucleotide microsatellites and BAT-26, and frameshift mutations of transforming growth factor-beta type II receptor. The relation between BAT-26 alterations and relevant clinicopathological or genetic parameters were analyzed.
  
  
  RESULTS
  Gastric cancer with BAT-26 alterations was highly correlated with multiple microsatellite alterations (> or = 3 loci) and frameshift mutations of transforming growth factor-beta type II receptor, and predominantly showed antral location, intestinal histologic subtype, advanced stage, a higher rate of Helicobacter pylori infection, a better postoperative survival and less lymph node metastasis.
  
  
  CONCLUSIONS
  These results show testing of BAT-26 alterations is a convenient and rapid screening method for identifying a subset of gastric cancer with a mutator phenotype and better prognosis.
authors.affiliation: Department of Internal Medicine, National Taiwan University Hospital, No. 7 Chun-Shan S. Rd., Taipei, Taiwan.
authors.forename: Ming-Shiang
authors.initials: MS
authors.lastname: Wu
authors.forename: Chung-Wei
authors.initials: CW
authors.lastname: Lee
authors.forename: Jin-Chuan
authors.initials: JC
authors.lastname: Sheu
authors.forename: Chia-Tung
authors.initials: CT
authors.lastname: Shun
authors.forename: Hsiu-Po
authors.initials: HP
authors.lastname: Wang
authors.forename: Ruey-Long
authors.initials: RL
authors.lastname: Hong
authors.forename: Wei-Jei
authors.initials: WJ
authors.lastname: Lee
authors.forename: Jaw-Town
authors.initials: JT
authors.lastname: Lin
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000382:microbiology / Q000473:pathology / Q000601:surgery; D000368:Aged; D004268:DNA-Binding Proteins; D005260:Female; D016368:Frameshift Mutation / Q000235:genetics; D005743:Gastrectomy; D005819:Genetic Markers / Q000235:genetics*; D016481:Helicobacter Infections / Q000235:genetics; D016480:Helicobacter pylori; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D018895:Microsatellite Repeats / Q000235:genetics*; D008875:Middle Aged; D051718:MutS Homolog 2 Protein; D009361:Neoplasm Invasiveness; D011184:Postoperative Period; D011379:Prognosis; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics; D013274:Stomach Neoplasms / Q000235:genetics* / Q000382:microbiology / Q000473:pathology / Q000601:surgery; D016019:Survival Analysis
chemical_list: D004268:DNA-Binding Proteins; D005819:Genetic Markers; D011518:Proto-Oncogene Proteins; D018125:Receptors, Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II; C497172:MSH2 protein, human; D051718:MutS Homolog 2 Protein